<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20111102007984N31</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-01-14</date_registration>
      <primary_sponsor>Iran University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of the effect of lumbar spinal nerve root block by transforminal and codal method on nerve involved in low back pain</public_title>
      <acronym></acronym>
      <scientific_title>The comparison of targeted spinal nerve root blockade with caudal vs transforaminal approach in lumbar radiculopathy</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-02-20</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>50</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/53618</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: In this study, we use the block randomization method so that after selecting patients according to the inclusion and exclusion criteria by selecting numbers from the table of random numbers and adapting to the blocks, patients are divided into study groups.
To randomize the two treatment methods, we create 4 blocks in six different states, then select a number using the table of numbers, and determine the study groups by matching the numbers with the blocks.
For example, if the first digit of our number is 1 to 6, select a block and the division is done, but if, for example, our number is 94071, the digit 9 is not valid and we select the next digit.
  Here, based on the block, we divide 4 people into groups.
1. TTCC 2. TCTC 3. TCCT
4. CCTT 5. CTCT 6. CTTC, Blinding description: In this study, people who are responsible for patient care and analysis of statistical data do not know about the treatment process and study groups, and information is provided to them in groups A and B.</study_design>
      <phase>2-3</phase>
      <hc_freetext>Lumbar spinal nerve root block, Transforminal, Kudal, Lumbar radiculopathy.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Intervention group: In Transforaminal group, blunt curved tip Racz needle G21 is introduced for each involved levels, under transverse process and pedicle conjunction by tunnel view, and after confirmation of correct position of the tip of needle transuraminal block injection solution is administered slowly. The solution for injection in the triamcinolone group (T) contains 20 mg of triamcinolone (triamcinolone acetonide, elixir, Iran) and 0.2% rupivacaine 5 ml (rupivacaine multeni, Italy). In case of involvement of more than one spinal nerve root, the same amount is prescribed for the next levels (up to two levels, one or two sides). In the caudal group (C), the injection is the same as for the transformaminal group for each level. Intervention 2: Control group: In the caudal group, the Racz epidural needle No. 17G enters the caudal space, and the Racz catheter enters the caudal space, and is guided to each level involved, and the drug is injected into the affected surface.Injected drugs include 20 mg of triamcinolone (triamcinolone acetonide, elixir, Iran) and 5 ml of 0.5% ropivacaine (rupivacaine multeni, Italy).</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Some part of the clinical information of the patients will be shared

When:
One year after the end of the project

To whom:
Faculty Members of Medical Sciences Universities

Conditions:
For further studies

Where to obtain:
Deputy of Research &amp; Technology, and Pain Research Center, Iran University of Medical Sciences

How to obtain:
First, at the request of the university, she/he will be informed at the request of the university's deputy of the research department, and then she/he will be referred to the pain research center during the administrative process and the data will be received by the committee of the pain research center of the center with a commitment and acceptance.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Farnad Imani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Pain Research Center, Rasool  Akram Hospital, Niayesh St. Sattarkhan St.</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۱۴۴۹۶۱۴۵۳۵</zip>
        <telephone>+98 21 6651 5758</telephone>
        <email>farnadimani@yahoo.com</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Farnad Imani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Hazrate Rasoole Akram Hospital,Niayesh St,Satarkhan Av, Tehran, 1449614535, IRAN</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۱۴۴۵۶۱۳۱۳۱</zip>
        <telephone>+98 21 6651 5758</telephone>
        <email>farnadimani@yahoo.com</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Radicular unilateral or bilateral low back pain more than six months
Maximum two levels involved
Age 40 to 70 years
Lack of response to conservative therapy after three months
ASA I-II
Moderate to sever pain (VAS &gt; 3)</inclusion_criteria>
      <agemin>40 years</agemin>
      <agemax>70 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Severe spinal deformity
Spinal tumors
Spine fracture
Vertebral listاsis more than G II
Local or systemic infection
Taking anticoagulants
Drug abuse
History of allergic reaction to the studied drugs
History of severe psychological disorders
Pregnancy and lactation
Severe or sudden onset of neurological complications such as urinary or fecal incontinence
BMI&gt;35
Patient refusal
MRI contraindication such as pacemakers, defibrillators, aortic aneurysm clips
Respiratory incompetence cause prone position intolerance
Smoking or alcohol consumption
History of lumbar spine surgery
Peripheral neuropathy such as diabetes</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>M54.5</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Low back pain</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Intervention group: In Transforaminal group, blunt curved tip Racz needle G21 is introduced for each involved levels, under transverse process and pedicle conjunction by tunnel view, and after confirmation of correct position of the tip of needle transuraminal block injection solution is administered slowly. The solution for injection in the triamcinolone group (T) contains 20 mg of triamcinolone (triamcinolone acetonide, elixir, Iran) and 0.2% rupivacaine 5 ml (rupivacaine multeni, Italy). In case of involvement of more than one spinal nerve root, the same amount is prescribed for the next levels (up to two levels, one or two sides). In the caudal group (C), the injection is the same as for the transformaminal group for each level.</i_keyword>
      <i_keyword>Control group: In the caudal group, the Racz epidural needle No. 17G enters the caudal space, and the Racz catheter enters the caudal space, and is guided to each level involved, and the drug is injected into the affected surface.Injected drugs include 20 mg of triamcinolone (triamcinolone acetonide, elixir, Iran) and 5 ml of 0.5% ropivacaine (rupivacaine multeni, Italy).</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Visual Analogue Scale. Timepoint: Before, two weeks and one month, and three months after the procedure. Method of measurement: based on questionnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Oswestry Disability Index. Timepoint: One, and three months after the procedure. Method of measurement: Based on the questionnaire.</sec_outcome>
      <sec_outcome>The amount of analgesia consumption. Timepoint: One, and three months after the procedure. Method of measurement: Record and take notes.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Iran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-01-11</approval_date>
        <contact_name>Iran University of Medical Sciences, Tehran, Iran</contact_name>
        <contact_address>Rasool Akram Hospital, Niayesh St, Satarkhan Av. Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
